Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BY-NCBleeding, Thrombosis and Vascular Biology

PO117 | LONGITUDINAL THROMBIN GENERATION PROFILING IN A PATIENT WITH SEVERE HEMOPHILIA A DURING ANTITHROMBIN-LOWERING THERAPY, CANCER, AND MAJOR SURGERY

Abstract

Background and aims. Thrombin generation (TG) represents one of the few functional assays available to assess the hemostatic balance in patients with hemophilia receiving non-replacement therapies. However, longitudinal data over extended periods and during major biological stressors such as cancer and surgery are limited. We aim to describe five-year longitudinal changes in plasma TG in a patient with severe hemophilia A receiving an siRNA-based antithrombin-lowering non-replacement therapy, including the impact of cancer diagnosis and major surgery. Methods. Serial TG measurements were performed in platelet-poor plasma from 2020 to 2025 using the calibrated automated thrombogram (CAT). TG was assessed at low (1 pM) and intermediate (5 pM) tissue factor (TF) concentrations at predefined clinical timepoints: pre-treatment, stable therapy, peri-cancer diagnosis, and post-surgical resection. Lag time, endogenous thrombin potential (ETP), peak thrombin, velocity index, and tail formation were analyzed. Antithrombin levels were measured in parallel. Pooled normal plasma was included as a reference. Written informed consent was obtained according to local ethical standards. Results. At 1 pM TF, a trend toward shorter lag time and higher peak thrombin was observed during the pre-tumor phase compared with stable therapy, while ETP remained non-measurable due to persistent thrombin activity. No relevant changes were observed around colorectal cancer diagnosis. Following colorectal cancer resection in March 2024, thrombin generation at 1 pM TF became fully measurable at the first post-surgical assessment, with ETP increasing from unmeasurable to 895 nM·min and late-phase tail formation (StartTail 55 min), despite only moderate peak thrombin (45 nM) (Figure 1). Antithrombin levels ranged between approximately 15–30% during stable follow-up before surgery and decreased to about 10-26% after surgery. At 5 pM TF, TG remained consistently high throughout the entire observation period, confirming preserved thrombin-generating capacity. Conclusions. In this long-term longitudinal case, colorectal cancer diagnosis was not associated with major changes in low-trigger TG, consistent with a localized disease stage. In contrast, surgical resection induced a distinct qualitative shift in TG dynamics, with the emergence of sustained thrombin activity despite moderate peak values. These findings suggest that, in pharmacologically rebalanced hemophilia, major biological stressors may primarily affect thrombin persistence rather than overall thrombin generation.

Related

  1. PO040 | PHARMACODYNAMIC CHARACTERIZATION OF THROMBIN GENERATION IN SEVERE HEMOPHILIA A PATIENTS ON EMICIZUMAB PROPHYLAXIS: A REAL-WORLD LONGITUDINAL STUDY
    Martina Bergamaschi
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  2. PO019 | LONGITUDINAL COAGULATION PROFILING BY THROMBIN GENERATION AND CIRCULATING MICROVESISCLES OF INDIVIDUALS UNDERGOING GENDER-AFFIRMING HORMONE THERAPY
    Elena Campello
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  3. PO056 | SYNERGISTIC EFFECT OF RECOMBINANT FACTOR INFUSION ON THROMBIN GENERATION IN HEMOPHILIA PATIENTS UNDER EMICIZUMAB OR CONCIZUMAB PROPHYLAXIS
    Matilde Capetta
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  4. Navigating anticoagulation in heart transplantation with thrombin–antithrombin complex: when conventional monitoring fails
    Chaonan Liu, Liqin Ling, Xunbei Huang +3
    Journal of Cardiothoracic SurgeryPeer-reviewedCC BYFull textSurgery & anaesthesiaDOAJ
  5. Fitusiran in Hemophilia: A Novel Therapeutic Approach Targeting Antithrombin
    Anna Dalton, Ryan Clark, Justin Arnall +2
    Journal of the Advanced Practitioner in OncologyPeer-reviewedCC BY-NC-ND 3.0Full textGeneral medicinePMC
BibTeX
@article{simion2026po117,
  title = {{PO117 | LONGITUDINAL THROMBIN GENERATION PROFILING IN A PATIENT WITH SEVERE HEMOPHILIA A DURING ANTITHROMBIN-LOWERING THERAPY, CANCER, AND MAJOR SURGERY}},
  author = {Chiara Simion},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  month = oct,
  url = {https://www.btvb.org/btvb/article/view/933},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - PO117 | LONGITUDINAL THROMBIN GENERATION PROFILING IN A PATIENT WITH SEVERE HEMOPHILIA A DURING ANTITHROMBIN-LOWERING THERAPY, CANCER, AND MAJOR SURGERY
AU  - Chiara Simion
PY  - 2026
DA  - 2026/10/26
JO  - Bleeding, Thrombosis and Vascular Biology
UR  - https://www.btvb.org/btvb/article/view/933
AB  - Background and aims. Thrombin generation (TG) represents one of the few functional assays available to assess the hemostatic balance in patients with hemophilia receiving non-replacement therapies. However, longitudinal data over extended periods and during major biological stressors such as cancer and surgery are limited. We aim to describe five-year longitudinal changes in plasma TG in a patient with severe hemophilia A receiving an siRNA-based antithrombin-lowering non-replacement therapy, including the impact of cancer diagnosis and major surgery. Methods. Serial TG measurements were performed in platelet-poor plasma from 2020 to 2025 using the calibrated automated thrombogram (CAT). TG was assessed at low (1 pM) and intermediate (5 pM) tissue factor (TF) concentrations at predefined clinical timepoints: pre-treatment, stable therapy, peri-cancer diagnosis, and post-surgical resection. Lag time, endogenous thrombin potential (ETP), peak thrombin, velocity index, and tail formation were analyzed. Antithrombin levels were measured in parallel. Pooled normal plasma was included as a reference. Written informed consent was obtained according to local ethical standards. Results. At 1 pM TF, a trend toward shorter lag time and higher peak thrombin was observed during the pre-tumor phase compared with stable therapy, while ETP remained non-measurable due to persistent thrombin activity. No relevant changes were observed around colorectal cancer diagnosis. Following colorectal cancer resection in March 2024, thrombin generation at 1 pM TF became fully measurable at the first post-surgical assessment, with ETP increasing from unmeasurable to 895 nM·min and late-phase tail formation (StartTail 55 min), despite only moderate peak thrombin (45 nM) (Figure 1). Antithrombin levels ranged between approximately 15–30% during stable follow-up before surgery and decreased to about 10-26% after surgery. At 5 pM TF, TG remained consistently high throughout the entire observation period, confirming preserved thrombin-generating capacity. Conclusions. In this long-term longitudinal case, colorectal cancer diagnosis was not associated with major changes in low-trigger TG, consistent with a localized disease stage. In contrast, surgical resection induced a distinct qualitative shift in TG dynamics, with the emergence of sustained thrombin activity despite moderate peak values. These findings suggest that, in pharmacologically rebalanced hemophilia, major biological stressors may primarily affect thrombin persistence rather than overall thrombin generation.
SN  - 2785-5309
ER  -